These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24720680)

  • 21. Discovery of novel tricyclic indole derived inhibitors of HCV NS5B RNA dependent RNA polymerase.
    Venkatraman S; Velazquez F; Gavalas S; Wu W; Chen KX; Nair AG; Bennett F; Huang Y; Pinto P; Jiang Y; Selyutin O; Vibulbhan B; Zeng Q; Lesburg C; Duca J; Huang HC; Agrawal S; Jiang CK; Ferrari E; Li C; Kozlowski J; Rosenblum S; Shih NY; Njoroge FG
    Bioorg Med Chem; 2013 Apr; 21(7):2007-17. PubMed ID: 23434368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Structure and replication of viral hepatitis C virus, the key of the future therapeutic goals].
    Grigorescu O; Luca CM; Moraru E
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(4):877-81. PubMed ID: 20209756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From basic molecular biology to curative antiviral therapy: the success story of Hepatitis C virology.
    Reddehase MJ
    Med Microbiol Immunol; 2019 Feb; 208(1):1-2. PubMed ID: 30328536
    [No Abstract]   [Full Text] [Related]  

  • 24. Small molecule and novel treatments for chronic hepatitis C virus infection.
    Harrison SA
    Am J Gastroenterol; 2007 Oct; 102(10):2332-8. PubMed ID: 17617208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings.
    Easterbrook P; Sands A; Harmanci H
    Semin Liver Dis; 2012 May; 32(2):147-57. PubMed ID: 22760654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Partnership to tackle HCV in low-income and middle-income countries.
    Das M
    Lancet Oncol; 2021 Sep; 22(9):1218. PubMed ID: 34391510
    [No Abstract]   [Full Text] [Related]  

  • 27. Non-nucleoside inhibitors of the HCV polymerase.
    Sarisky RT
    J Antimicrob Chemother; 2004 Jul; 54(1):14-6. PubMed ID: 15190019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of hepatitis C virus elimination in low- and middle-income countries.
    Razavi H
    J Viral Hepat; 2021 Feb; 28(2):445. PubMed ID: 33205589
    [No Abstract]   [Full Text] [Related]  

  • 29. Hepatitis C drugs not reaching poor.
    Callaway E
    Nature; 2014 Apr; 508(7496):295-6. PubMed ID: 24740042
    [No Abstract]   [Full Text] [Related]  

  • 30. [Advances in research of antiviral agents for hepatitis C].
    Kang FB; Zhao M
    Zhonghua Gan Zang Bing Za Zhi; 2006 Dec; 14(12):933-5. PubMed ID: 17196142
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmaceuticals. Advocates protest the cost of a hepatitis C cure.
    Cohen J
    Science; 2013 Dec; 342(6164):1302-3. PubMed ID: 24337268
    [No Abstract]   [Full Text] [Related]  

  • 32. A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.
    Lawitz EJ; Hill JM; Marbury T; Demicco MP; Delaney W; Yang J; Moorehead L; Mathias A; Mo H; McHutchison JG; Rodriguez-Torres M; Gordon SC
    Antivir Ther; 2013; 18(3):311-9. PubMed ID: 23047118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The science of direct-acting antiviral and host-targeted agent therapy.
    Pawlotsky JM
    Antivir Ther; 2012; 17(6 Pt B):1109-17. PubMed ID: 23188746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.
    Mo H; Yang C; Wang K; Wang Y; Huang M; Murray B; Qi X; Sun SC; Deshpande M; Rhodes G; Miller MD
    J Viral Hepat; 2011 May; 18(5):338-48. PubMed ID: 20456634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scaling-up HCV treatment to achieve WHO targets by 2030.
    Cooke GS
    Trop Med Int Health; 2017 Apr; 22(4):372-374. PubMed ID: 28072498
    [No Abstract]   [Full Text] [Related]  

  • 36. Hepatitis C drug affordability.
    Kamal-Yanni M
    Lancet Glob Health; 2015 Feb; 3(2):e73-4. PubMed ID: 25617196
    [No Abstract]   [Full Text] [Related]  

  • 37. Optimizing workflow at a multidisciplinary clinic for management of hepatitis C virus infection.
    Grischeau M; Zenner J
    Am J Health Syst Pharm; 2012 Dec; 69(24):2131-3. PubMed ID: 23230034
    [No Abstract]   [Full Text] [Related]  

  • 38. Viral hepatitis: Scaling up HCV treatment in resource-limited countries.
    Lemoine M; Thursz M
    Nat Rev Gastroenterol Hepatol; 2015 Apr; 12(4):193-4. PubMed ID: 25708046
    [No Abstract]   [Full Text] [Related]  

  • 39. Access to hepatitis C medicines.
    Edwards DJ; Coppens DG; Prasad TL; Rook LA; Iyer JK
    Bull World Health Organ; 2015 Nov; 93(11):799-805. PubMed ID: 26549908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crunching the numbers for viral hepatitis.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):875. PubMed ID: 34626556
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.